medigraphic.com
Colegio de Medicina Interna de México.

2010, Number 2

<< Back Next >>

Med Int Mex 2010; 26 (2)

Cognitive disorders prevalence in patients with HIVAIDS in a Mexican cohort

Galindo SJ, Rodríguez AJV, Sandoval RJL, Tejada GRA

Language: Spanish
References: 53
Page: 116-122
PDF size: 316.41 Kb.


ABSTRACT

Background: The HIV associated cognitive disorders cause combined acquired cognitive deficit abilities that might include motor function, behavior and cognition, that contribute to the rising of HIV infection’s morbidity and it represents an important risk factor of mortality.
Materials and methods: Prospective Survey realized in the General Hospital 11 from the Mexican Institute of Social Security with population conformed by all the outpatient with HIV/AIDS diagnosis. Mini Mental State Exam (MMSE) was used to identify neurological alterations founded in this particular cohort.
Results: 119 patients were interviewed of which 91 were male and 28 female. The average age calculated in year at time of the study’s realization was 39.21 ± 10.3 and the time of treatment calculated in months was 63.63 ± 38.89. The study shows that 66% of the surveyed patients had a normal cognition capacity, in 22% of the cases presented a suspicion of pathology and 11% had cognition disorders. It wan not reported any dementia case.
Conclusions: In base to MMSE, 66% of our population had a normal cognition capacity; the rest of them had suspicion of pathology or cognition disorders.


REFERENCES

  1. McArthur JC, Hoover DR, Bacellar H, et al. Multicenter AIDS Cohort Study. Dementia in AIDS patients: incidence and risk factors. Neurology 1993;43:2245-2252.

  2. Justice AC, McGinnis KA, Atkinson JH, et al. Psychiatric and neurocognitive disorders among HIV – positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 2004;18 (suppl 1):S49-S59.

  3. Cliford BD. AIDS dementia. Med Clin N Am 2002;86:537- 550.

  4. Antinori A, Arendt G, Becker JT. Updated research nosology for HIV associated neurocognitive disorders. Neurology 2007;69:1789-1799.

  5. An SF, Giometto M, Miller RF, et al. Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS. J Neuropathol Exp Neurol 1997;56:1262-1268.

  6. Lipton SA, Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995;332:934- 940.

  7. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.

  8. Bacellar H, Muñoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1–related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994;44:1892- 1900.

  9. Goodwin GM, Pretsell DO, Chiswick A, et al. The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case control study of the evolution of dementia. AIDS 1996;10:431-440.

  10. Chiesi A, Vella S, Dally LG, et al. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:39-44.

  11. Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of _2-microglobulin and neopterin. J Infect Dis 1996;174:294-298.

  12. Bouwman FH, Skolasky RL, Hes D, et al. Variable progression of HIV-associated dementia. Neurology 1998;50:1814-1820.

  13. Qureshi AI, Hanson DL, Jones JL, Janssen RS. Estimation of the temporal probability of human immunodeficiency virus (HIV) dementia after risk stratification for HIV-infected persons. Neurology 1998;50:392-397.

  14. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607-613.

  15. D’Arminio MA, Duca PG, Vago L, Grassi MP, Moroni M. Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 2000;54:1856- 1859.

  16. Stern Y, McDermott MP, Albert S, et al. Factors associated with incident human immunodeficiency virus dementia. Arch Neurol 2001;58:473-479.

  17. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992;42:1472-1476.

  18. Wang F, So Y, Vittinghoff E, et al. Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:75-82.

  19. Goodkin K, Wilkie FL, Concha M, et al. Aging and neuro-AIDS conditions and the changing spectrum of HIV-1- associated morbidity and mortality. J Clin Epidemiol 2001;54 (Suppl. 1): S35-S43.

  20. Bell JE, Donaldson YK, Lowrie S, et al. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS 1996;10:493- 499.

  21. Wilkie FL, Goodkin K, Eisdorfer C, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci 1998;10:125-132.

  22. Beach RS, Morgan R, Wilkie F, et al. Plasma vitamin B12 level as a potential cofactor in studies of human immunodeficiency virus type 1–related cognitive changes. Arch Neurol 1992;49:501-506.

  23. Herzlich BC, Schiano TD. Reversal of apparent AIDS dementia complex following treatment with vitamin B12. J Intern Med 1993;233:495-497.

  24. Shor-Posner G, Morgan R, Wilkie F, Eisdorfer C, Baum MK. Plasma cobalamin levels affect information processing speed in a longitudinal study of HIV-1 disease. Arch Neurol 1995;52:195-198.

  25. Marder K, Sterh Y, Malouf R, et al. Neurologic and neuropsychological manifestations of human immunodeficiency virus infection in intravenous drug users without acquired immunodeficiency syndrome: relationship to head injury. Arch Neurol 1992;49:1169-1175.

  26. Poutiainen E. Cognitive deficits and emotional disorders in HIV-1 infected individuals. Acta Psychiatr Scand 1995;92:429- 435.

  27. Satz, Mongenstem H, Miller EN. Low education as possible risk factor for cognitive abnormalities in HIV-1: findings from the Multicenter AIDS Cohort Study (MACS). J Adquir Immune Defic Syndr 1993;6:503-511.

  28. Maj M, Satz P, Janssen R. WHO Neuropsychiatric AIDS Study, cross-sectional phase II: neuropsychological and neurological findings. Arch Gen Psychiatry 1994;51:51-61.

  29. Sterm RA, Silva SG, Chaisson N, Evans DL. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infectio. Arch Neurol 1996;53:148-153.

  30. Starace F, Baldassare C, Biancolili V. Early neuropsychological impairment in HIV-seropositive intravenous drugs users: evidence from the Italian Multicentre Neuropsychological HIV Study. Acta Psychiatr Scand 1998;97:132-138.

  31. Grant I, Heaton RK, Atkinson JH, for the HIV Neurobehavioral Research Center Group. Neurocognitive disorders in HIV-1 infection. Curr Top Microbiol Immunol 1995;202:11- 32.

  32. McArthur JC, Sacktor N, Selnes O. Human immunodeficiency virus-associated dementia. Semin Neurol 1999;19:129-150.

  33. Grassi MP, Perin C, Clerici F, et al. Neuropsychological performance in HIV-1-infected drug abusers. Acta Neurol Scand 1993;88:119-122.

  34. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003;9:205-221.

  35. Sacktor NC, Bacellar H, Hoover DR, et al. Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. J Neurovirol 1996;2:404-410.

  36. Albert SM, Marder K, Dooneief G, et al. Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Arch Neurol 1995;52:525-530.

  37. Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS 1999;13:1677-1685

  38. Ammassari AA, Starace F, Aloisi MS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002;59:1944-1950.

  39. Power C, Selnes OA, Grim JA, McArthur JC. The HIV Dementia Scale: a rapid screening test. J AIDS 1995;8:273-278.

  40. Davis HF, Skolasky RL , Selnes OA, et al. Assessing HIVassociated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002;12:29-31,38.

  41. Power C, Selnes OA, Grim JA, McArthur JC. The HIV Dementia Scale: a rapid screening test. J AIDS 1995;8:273-278.

  42. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367-1374.

  43. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.

  44. Bleecker ML, Bolla-Wilson K, Kawas C, Agnew J. Agespecific norms for the Mini-mental State Exam. Neurology 1988;38:1565-1568.

  45. Lobo A, Ezquerra J, Gomez F, et al. El Mini-Examen Cognoscitivo (Un test sencillo, práctico, para la detección de alteraciones intelectuales). Actas Luso-Españolas Neurol Psiquiat 1979;7:189-202.

  46. Lobo A, Saz P, Marcos G, et al. Revalidación y normalización del mini-examen cognoscitivo (primera versión en castellano del MMSE) en población general geriátrica. Med Clin 1999;20:767-774.

  47. Quiroga P, Albala C, Klaasen G. Validación de un test de tamizaje para el diagnóstico de demencia asociada a edad, en Chile. Rev Méd Chile 2004;132:467-478.

  48. Velásquez-Monrroy O, Rosas PM, Lara E, Pastelín HG, grupo ENSA 2000. Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002;72:71-84.

  49. Deshpande AK, Patnaik MM. Non opportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study. Med Gen Med 2005;7:2.

  50. Dore GJ, Correll OK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antirretroviral therapy. AIDS 1999;13:1249-1253.

  51. Wong MH, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007;68:350-355.

  52. Riedel D, Ghate M, Nene M, et al. Screening for human immunodeficiency virus (HIV) dementia in an HIV clade Cinfected population in India. J Neurovirol 2006;12:34-38.

  53. McMurtray A, Clark DG, Christine D, Mendez MF. Early-onset dementia: frequency and causes compared to late-onset dementia. Dement Geriatr Disord 2006;21:59-64.




2020     |     www.medigraphic.com